Menu Search
Equities

Checkpoint Therapeutics Inc

CZTA:MUN

Checkpoint Therapeutics Inc

Actions
  • Price (EUR)1.62
  • Today's Change0.14 / 9.49%
  • Shares traded-1.00
  • 1 Year change-36.78%
  • Beta--
Data delayed at least 15 minutes, as of May 17 2024 07:06 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Checkpoint Therapeutics, Inc. is a clinical-stage immunotherapy and targeted oncology company focused on the acquisition, development and commercialization of novel treatments for patients with solid tumor cancers. The Company is evaluating its lead antibody product candidate, cosibelimab, a potential best-in-class anti-programmed death-ligand 1 (PD-L1) antibody licensed from the Dana-Farber Cancer Institute, as a potential new treatment for patients with selected recurrent or metastatic cancers, including metastatic and locally advanced cutaneous squamous cell carcinoma. The Company is also evaluating its lead small-molecule, targeted anti-cancer agent, olafertinib, a third-generation epidermal growth factor receptor (EGFR) inhibitor, as a potential new treatment for patients with EGFR mutation-positive non-small cell lung cancer. Its anti-GITR monoclonal antibody, CK-302, is a fully human agonistic antibody that is designed to bind to and trigger signaling in GITR expressing cells.

  • Revenue in USD (TTM)68.00k
  • Net income in USD-52.32m
  • Incorporated2014
  • Employees23.00
  • Location
    Checkpoint Therapeutics Inc95 SAWYER ROAD, SUITE 110WALTHAM 02453United StatesUSA
  • Phone+1 (781) 652-4500
  • Fax+1 (302) 531-3150
  • Websitehttps://checkpointtx.com/
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.